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ABSTRACT:
Melanoma is a devastating skin cancer characterized by distinct biological subtypes. 
Besides frequent mutations in growth- and survival-promoting genes like BRAF and 
NRAS, melanomas additionally harbor complex non-random genomic alterations. 
Using an integrative approach, we have analysed genomic and gene expression 
changes in human melanoma cell lines (N=32) derived from primary tumors and 
various metastatic sites and investigated the relation to local growth aggressiveness 
as xenografts in immuno-compromised mice (N=22). Although the vast majority 
(>90%) of melanoma models harbored mutations in either BRAF or NRAS, significant 
differences in subcutaneous growth aggressiveness became obvious. Unsupervised 
clustering revealed that genomic alterations rather than gene expression data reflected 
this aggressive phenotype, while no association with histology, stage or metastatic 
site of the original melanoma was found. Genomic clustering allowed separation of 
melanoma models into two subgroups with differing local growth aggressiveness 
in vivo. Regarding genes expressed at significantly altered levels between these 
subgroups, a surprising correlation with the respective gene doses (>85% accordance) 
was found. Genes deregulated at the DNA and mRNA level included well-known cancer 
genes partly already linked to melanoma (RAS genes, PTEN, AURKA, MAPK inhibitors 
Sprouty/Spred), but also novel candidates like SIPA1 (a Rap1GAP). Pathway mining 
further supported deregulation of Rap1 signaling in the aggressive subgroup e.g. by 
additional repression of two Rap1GEFs. Accordingly, siRNA-mediated down-regulation 
of SIPA1 exerted significant effects on clonogenicity, adherence and migration in 
aggressive melanoma models. Together our data suggest that an aneuploidy-driven 
gene expression deregulation drives local aggressiveness in human melanoma.
INTRODUCTION
Melanomas account for 4 to 5% of all cancers and 
represent currently the 6th leading cancer type in the USA 
[1]. While 80% of melanomas are diagnosed at localized 
stages, one third of those early stage patients will develop 
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metastatic disease associated with dismal prognosis, i.e. 
a median overall survival of 6 to 8 months [2]. Recent 
discoveries have markedly improved our understanding 
of the molecular changes underlying malignant 
progression of melanomas including mainly alterations in 
proliferation, survival and cell death signaling pathways 
[3-5]. The RAF/MEK/ERK and PI3K/AKT are two 
major signaling pathways constitutively activated in up 
to 90% of melanomas. While BRAF mutations represent 
the most frequent oncogenic alteration in melanomas so 
far (BRAFV600E in up to 70% of cases), NRAS mutations 
occur in 15 to 30%. Recently, exon sequencing approaches 
revealed additional mutations in individual members of 
the MAP3K and MAP2K families including MEK1 and 
MEK2. The AKT/mTOR pathway might be additionally 
activated mainly by loss-of-function mutations or deletions 
of the inhibiting phosphatase PTEN. Furthermore, typical 
impairment of senescence due to mutations, deletions or 
methylation of p16INK4/CDKN2A occurs in 30 to 70% of 
melanomas. Oncogenic proteins in melanoma include 
e.g. members of the bcl-2 protein family, cyclin D1, 
and several transcription factors like the lineage-specific 
oncogene MITF (for detailed reviews on these molecular 
changes see [6-8]).
Improving the knowledge on major drivers 
underlying development and aggressiveness of 
melanoma is of strong interest to identify clinically and 
therapeutically relevant patient subgroups. However, 
achievement of this goal is hampered by strong 
heterogeneity not only at the genomic level, but also 
with regard to phenotypic, histopathological, and clinical 
characteristics. Accordingly, multiple studies from 
different scientific disciplines have suggested the existence 
of several melanoma subtypes that may arise through 
several different causative pathways [9]. At the molecular 
level, besides (in)activating mutations in proto-oncogenes 
and tumor suppressor genes, development of melanoma 
is characterized by complex karyotypic changes leading 
to multiple and severe gene dose alterations. Several lines 
of evidence suggest that this aneuploidy might represent 
an additional driving force of malignant transformation 
and cancer progression [7, 9]. It can be assumed that 
the observed molecular heterogeneity drives at least to 
some extent disease pathogenesis, clinical behavior, and 
Figure 1: Subcutaneous growth of the indicated 11 human melanoma cell models in immuno-compromised mice. (A) 
As described in Material and Methods, 2.5x106 melanoma cells were xenografted into immuno-compromised mice and local tumor growth 
was measured at the indicated time points. (B) Representative H&E staining of the fast-growing melanoma xenograft model VM-21 
characterized by invasive growth subcutaneously (left) and causing lung metastasis (right panel).  
0
2000
4000
6000
8000
10000
0 10 20 30 40 50 60 70 80 90 100 110
VM-10
VM-24
VM-7
VM-48
VM-1
VM-28
VM-23
VM-30
VM-21
VM-47
VM-4
Day Post Tumor Graft 
M
ea
n 
Tu
m
or
 V
ol
um
e 
(m
m
³) 
A  
B 
Oncotarget 2012; 3:  399-413401www.impactjournals.com/oncotarget
possibly response to therapy, and that genomic aberrations 
and gene dose-related RNA alteration patterns might even 
dictate disease behavior [7]. Accordingly, clustering of 80 
metastatic lesions based on genomic alteration profiles 
resulted in three subgroups that could not be related to 
their location, but, when intersected with clinical outcome, 
one subgroup displayed a significant survival advantage, 
indicating that the clustering could be biologically relevant 
[7].
In this study, we aimed to analyze genomic and 
transcriptomic alterations in human melanoma cell 
cultures (originating from primary as well as metastatic 
lesions) classified with respect to their in vivo growth 
characteristics. Using this approach, we demonstrated 
that genomic aberrations allow clustering of primary 
melanoma cell lines according to their in vivo growth 
behavior. Interestingly, genes differentially expressed in 
subgroups with differing aggressiveness closely reflected 
corresponding gene dose alterations. This suggests 
that melanoma malignancy is at least partly driven by 
aneuploidy-mediated gene expression deregulation. The 
affected genes comprised several known oncogenes 
and tumor-suppressors. However, also novel candidates 
like SIPA1, a Rap1GTPase, were identified as important 
drivers of melanoma aggressiveness. Accordingly, by 
using a siRNA approach, this Rap1-deactivating protein 
was proven to regulate clonogenicity and cell adhesion/
migration of aggressive melanoma cell models. 
RESULTS
Human melanoma xenograft models 
are characterized by distinctly differing 
aggressiveness
In an initial approach, 11 human cutaneous 
melanoma cell models were xenografted subcutaneously 
into immuno-compromised nu/nu mice and primary tumor 
Figure 2: Differentially expressed genes (Student`s t-test, p<0.01; N=428 probes) in the “fast” versus the “slow” 
melanoma subgroups are not randomly distributed across the chromosomes. (A) Percentage of all genes located at the indicated 
chromosome arms as compared to the percentage of changed genes are indicated by open and black bars, respectively. Chromosome arms 
with highly increased aberration ratios are indicated (black arrows).  (B) Fold changes in the expression levels for the 428 probes in the 
fast- versus slow-growing subgroup are mapped to the respective chromosomal regions. (C) The percentage of genes significantly up- or 
downregulated in the fast- versus slow-growing melanoma subgroup at the indicated chromosomal arms were calculated. 
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Figure 3: DNA gains and losses analysed by array CGH in melanoma models and association with aggressiveness. (A) 
GISTIC analyses are shown for the 11 melanoma models (upper panel), and for the 5 fast- and the 6 slow-growing models (middle and 
lower panel, respectively). SGOL scores were calculated using a modified version of the GISTIC algorithm using the “SGOLscore” function 
(see Material and Methods). (B) Unsupervised clustering (WECCA, see Materials and Methods) of the melanoma models with respect to 
the array CGH data are shown. “Fast” melanoma models are indicated by red and “slow” ones by blue boxes. Colored arcs indicate the 
histology/metastatic site of the melanoma models: red, primary nodular melanomas; black, primary superficial spreading melanoma; blue, 
lymph node metastasis; green, brain metastasis. (C) The heatmap depicts probes (N=120) significantly (p<0.001, Student´s t test) differing 
in array CGH analysis between the fast- versus slow-growing melanoma subgroups. The predominantly affected chromosomal regions are 
indicated at the right.
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growth as well as metastasis to the lungs, the liver and the 
brain investigated. While all cell lines were tumorigenic, 
distinct differences in aggressiveness became obvious 
(Figure 1A). Five cell models were characterized by 
rapid growth with two showing spontaneous metastasis to 
the lung (Figure 1B). In contrast, the other 6 melanoma 
models, though all tumorigenic, were much less 
aggressive and no signs of local or distant metastases 
could be detected. Growth behaviour was confirmed in 
the SCID mouse system (data not shown). Tumorigenicity 
in vivo did not reflect the growth characteristics of the 
cell models in vitro regarding minimal doubling time 
(data not shown and [10]). This suggests that specific 
tumor cell characteristics and/or interactions with the 
microenvironment are the major determinants causing the 
significant differences of tumor aggressiveness in vivo. 
A 
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Figure 4: Genomic alterations allow prediction of local growth aggressiveness of human melanoma models in immuno-
compromised mice. (A) Unsupervised clustering of the original 11 (solid boxes; red and blue indicate fast- versus slow-growing, 
respectively) and the additional 21 melanoma cell models was performed based on array CGH data. Those melanoma models selected for 
validation in xenograft growth are indicated by dashed outlines. (B) Xenograft growth characteristics of the melanoma models selected 
for validation are shown. (C) Clustering of the 32 melanoma models by array CGH data based on probes (N=62; “genomic identifier”) 
differing at p<0.0005 (Student´s t-test) between the fast- versus the slow-growing subgroup of the original 11 melanoma cell models. The 
corresponding heatmap and dendrogram are shown. (D) Assignment of the melanoma cell models to the two clusters generated by the 
genomic identifier probe set. (E) Mean tumor growth from the day of measurable tumor detection of the 9 melanoma xenografts assigned 
to cluster A (red line) and the 12 xenografts to cluster B (black line) is shown. 
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Genes differentially expressed in fast- versus slow-
growing melanoma models are non-randomly 
distributed along the chromosomes
In order to determine cellular factors driving 
in vivo tumor aggressiveness, whole-genome gene 
expression arrays were performed. The 11 melanomas 
were subgrouped into “fast-growing” and “slow-
growing” models according to xenotransplant growth 
dynamics (compare Figure 1A) in order to extract 
differentially expressed genes (Student´s t-test p<0.01, 
428 oligonucleotide probes representing 323 genes). 
When allocating this set of probes to the chromosomal 
arms, a strikingly non-random distribution was detected 
(Figure 2A,B). First, when comparing the proportion 
of significantly changed probes per arm with that of 
all oligonucleotides represented on the microarray, 
chromosome arms with distinct enrichment of altered 
gene expression in fast- versus slow-growing melanomas 
became obvious (Figure 2A). Hotspots were chromosomes 
2, 10, 11 and 22 as well as 17p and 19p arms. Also the 
direction (up- or down-regulation) of the significant gene 
expression changes was non-randomly distributed along 
the chromosomes (Figure 2B,C). Thus, for example 
altered genes on chromosomes 10, 2p, and 22 were almost 
generally expressed at lower levels in the fast-growing 
subgroup (39/41; 25/25; 18/18, respectively). In contrast, 
on chromosome 11 all but one concerned oligonucleotides 
(47/48) indicated a significantly higher expression in 
the aggressive melanoma subgroup (Figure 2C). Taken 
together these data suggest that genomic/chromosomal 
alterations might have a direct impact on the gene 
expression pattern associated with in vivo aggressiveness 
of human melanoma models.
Genomic gains and losses but not mRNA 
expression patterns cluster with aggressiveness in 
xenotransplantation models
Based on the striking non-random association 
of genome-wide gene expression with chromosomal 
regions, we decided to perform array CGH analyses to 
investigate genome-wide changes in gene copy numbers. 
All melanoma models exhibited multiple chromosomal 
changes involving the classical characteristics of human 
melanoma cells like gains in chromosomes 6p, 7 and 20 
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as well as losses in 9p, 10 and 14. Array CGH data for 
the three representative melanoma models VM-4, VM-7 
and VM-24 are shown in Supplementary Figure S1. A 
summary of array CGH data for all 11 melanoma models 
based on GISTIC analysis is presented in Figure 3A (upper 
panel). When comparing genomic changes in fast- versus 
slow-growing melanoma cell models by GISTIC (Figure 
3A, middle and lower panel), several differences appeared. 
While the p16/ARF locus at chromosome 9p was equally 
lost in both subgroups, deletions at the PTEN locus at 
10q were more pronounced in the aggressive melanomas. 
Moreover, more extended losses of chromosome 10 and 
gains of chromosomes 20q and parts of 11q characterised 
the aggressive melanoma models. In contrast, losses in 6q 
were more apparent in the less aggressive subgroup.
In order to find out whether genomic changes 
and/or mRNA expression levels in melanoma models 
indicate histological origin and/or tumor type, we 
performed unsupervised cluster analyses on array CGH 
(Figure 3B) and gene expression data (Supplementary 
Figure S2). Concerning genomic alterations, clustering 
of melanoma models reflected neither the histological 
origin nor the metastatic site, but - with one exception 
– growth aggressiveness in vivo. This was in contrast to 
the gene expression analyses, where no association with 
aggressiveness in the mouse models could be found. 
Upon closer inspection of those genomic regions differing 
significantly (p<0.001) in gene dose between the two 
subgroups of melanomas, again a strong prevalence of 
selected chromosomal arms became visible with a focus 
Figure 5: Aneuploidy-driven gene expression deregulation underlies aggressiveness of melanoma xenograft models. 
(A) Genes (191 probes covering 180 genes) differing in mean expression values between the two melanoma subgroups at a significance 
level of p<0.005 (Student´s t-test, log2 of fold-change, black dots) are blotted for the most informative chromosomes against the mean array 
CGH aberration scores (log2) for fast- (red lines) and slow-growing (blue lines) melanoma cell models. Accordingly, a value of 1 indicates 
a two-fold increase and -1 a two-fold decrease in mean expression level in the fast- versus the slow-growing subcluster. In contrast, array 
CGH data indicate mean (log2) gains/losses in the two melanoma subgroups as compared to normal control DNA pooled from healthy 
donors. Consequently, a value of 1 indicates a two-fold increased copy number of the respective chromosomal region in the indicated 
melanoma subcluster. (B) Expression levels of three selected genes from Supplementary Table S2 were evaluated by real-time RT-PCR and 
mean deltaCT values in the fast- versus the slow-growing subclusters are shown.
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on changes in chromosomes 2, 6, 10, 11 and X (Figure 
3C).
Genomic alteration signature predicts 
aggressiveness of melanoma xenograft models
To test whether the genomic signature of the original 
11 melanoma models allows prediction of aggressiveness 
in further melanoma models, genomic DNA isolated 
from 21 additional melanoma primary cell cultures was 
analysed by array CGH. As a first strategy, unsupervised 
clustering using the complete array CGH data set was 
performed in all 32 melanoma models (Figure 4A). 
Again the previously identified fast-growing cell models 
tended to cluster together in subgroups (solid-lined boxes) 
including also novel melanoma models. Consequently, we 
chose three additional cell models clustering with the fast- 
and two with the slow-growing subgroup (broken lined 
boxes in Figure 4A) and tested them for tumor growth in 
SCID mice. Indeed, a strong difference was found within 
this “validation set” with VM-8, VM-14 and VM-15 being 
highly aggressive while VM-44 formed slow-growing 
tumors and VM-54 was not tumorigenic within the time 
period of analysis (Figure 4B). In a second approach, we 
aimed to develop a less complex “genomic signature” from 
the original 11 melanoma models. Consequently, a highly 
stringent analysis at the single probe level extracting 
those probes differing between the two subgroups with a 
Figure 6: The Rap1 deactivator SIPA1 is gained at the DNA level as well as overexpressed in aggressive melanoma 
models and impacts on cell behaviour. (A) Deregulation of Rap1 activity regulating molecules at the mRNA expression level in 
the fast- versus the slow-growing melanoma models. Red circles indicate significant changes (p<0.05) and the direction of the changes 
in fast- versus slow-growing melanoma models is indicated. (B) Immunodetection of SIPA1 in a “fast” (VM-8) and a “slow” (VM-28) 
melanoma xenograft tumor is shown. (C) SIPA1 and Rap1 expression was detected by Western blot analysis in the original 11 melanoma 
cell lines grouped with regard to growth aggressiveness. (D) Knock-down of SIPA1 expression was performed using siRNA. Two examples 
of fast-growing melanoma models are shown. (E) Cell adhesion in a “fast” (VM-1) and a “slow” (VM-28) melanoma cell line transfected 
with scrambled (scr) and SIPA1 siRNA was determined at 3 h and 24 h after seeding. (F) The impact of SIPA1 knock-down by siRNA on 
clonogenic potential was measured in the aggressive melanoma cell line VM-1. The total colony numbers (left panel) and the number of 
large colonies (≥50 cells, right panel) were counted. (G) Impact of SIPA1 siRNA-mediated knockdown on migration potential of “fast” 
as compared to “slow” melanoma cells was investigated using transwell chamber assays. All experiments were performed three times and 
means ± SD are shown.  
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p<0.0005 (Student´s t-test) was performed. This resulted 
in 62 probes representing 50 annotated gene loci (termed 
“CGH-identifier”) (Supplementary Table S2). Cluster 
analyses of all available 32 melanoma models with this 
CGH-identifier led to formation of two distinct subgroups 
termed cluster A and B (Figure 4C,D). Consistent 
with unsupervised clustering results, cluster A (N=13) 
contained all five fast-growing and cluster B (N=19) all 
six slow-growing members of the original 11 melanoma 
models. Of the additional 21 models, 9 grouped in cluster 
A and 12 in cluster B including correct allocation of the 
5 melanoma models used as validation set (compare 
Figure 4B). The growth dynamics of these melanoma 
clusters in SCID mice (Fig. 4E) clearly reflected the 
highly significant difference in tumor growth between the 
two subgroups. These data indicate that a defined set of 
chromosomal changes can predict in vivo aggressiveness 
of human melanoma cells.
Significant gene expression differences between 
fast- versus slow-growing melanoma models are 
reflected by gene dose alterations
Next we re-evaluated gene expression differences 
between the melanoma subgroups at higher stringency 
(p<0.005 ; Student´s t-test). This analysis resulted in 191 
probes representing 180 differentially expressed genes. 
Figure 5 depicts expression changes of these genes (log2 
of fold-change, black dots in Figure 5A) plotted for the 
most informative chromosomes along the mean array CGH 
aberration scores (log2) for fast- versus slow-growing 
melanoma subgroups (red and blue lines, respectively, 
in Figure 5A). A surprisingly good reflection of the 
expression levels by gene copy numbers was observed for 
the majority of genes. Only 15.4 % of all 191 significantly 
changed probes at the mRNA level did not correspond to 
a respective change at the DNA level. Interestingly, these 
few genes were mainly localised on three chromosomes/
arms, namely 1p, 21q, and X. In contrast, the vast majority 
or even all significant expression changes at several 
chromosomal arms were reflected by DNA dose both 
in terms of gains and losses, like chromosome 2 (29/32 
agreeing), chromosome 6 (9/9 agreeing), chromosome 10 
(18/19 agreeing), chromosome 11 (28/28 agreeing) and 
chromosome 17 (14/15 agreeing). This again indicates that 
large scale gains/losses at several specific chromosomal 
regions are involved in driving local aggressiveness of 
melanoma xenograft models. 
Gene expression differences between fast- 
versus slow-growing melanoma models suggest 
alterations in cellular growth and differentiation 
networks
Next we analysed expression array data by in silico 
pathway prediction approaches for genes expressed 
differentially between the 8 fast - and 8 slow-growing 
models (including the original 11 models and the 5 
models of the validation set) (Student`s t-test, p<0.05). 
This resulted in the identification of 2165 altered probes, 
which were imported into Ingenuity Pathway Analysis 
software. Regarding biological functions this approach 
suggested beside “cancer” also both “dermatological” 
and “neuronal diseases”. Altered networks involved Ras 
and negative MAPK regulators like Sprouty (Spry) and 
Spred proteins as well as Ras/Rap/Rab GTPase protein 
families, suggesting deregulation of these gene products to 
contribute significantly to melanoma model aggressiveness 
in vivo (Supplementary Figure S3A,B).
Genes altered at gene dose and expression level 
between fast- versus slow-growing melanoma 
models: SIPA1 as example
To identify factors underlying the predictive power 
of genomic alteration patterns, we aimed to investigate the 
reflection of gene expression changes in the corresponding 
gene doses. In order to extract genes or pathways from 
the genomic signature which determine the observed 
aggressiveness, again two approaches were followed. First, 
those genes altered at both the DNA and mRNA level were 
evaluated with comparably low stringency (genomic level: 
p<0.01; expression level p<0.05). This analysis resulted 
in the selection of 116 probes, which were predominantly 
located on chromosomal regions 11q12-q14, 10p, and 
6q. Pathway identification using the Ingenuity Pathway 
Analysis software revealed several significant pathways 
involving regulators of GTPases like Rap1 (SIPA1, a 
RapGAP protein, and RapGEF2) (Supplementary Figure 
S4), which pointed toward a significant impact of Rap1 
deregulation on melanoma model aggressiveness in vivo.
In a second approach the evaluation was repeated 
at higher stringency (genomic level: p<0.005; expression 
level p<0.005). This approach resulted in only 18 probes/
genes that were highly significantly changed both on DNA 
and mRNA levels (Supplementary Table S3). Within this 
set of genes, six were expressed at lower levels in the 
aggressive melanoma models, 5 of which were localized 
on chromosome 10. Genes expressed at higher levels 
were predominantly (9 of 12 oligonucleotides) located 
on chromosome 11q13. In order to validate the genes 
with the highest significance, real-time PCR experiments 
for three selected genes were performed. Statistically 
significantly increased expression of SIPA1 and NUS1 
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in the fast-growing melanoma subcluster was confirmed, 
while down-regulation of DNAJC1 was also seen in this 
analysis but did not reach significance (Figure 5B). 
Gene expression analysis did not only indicate 
significant overexpression of the Rap1-inactivating 
protein SIPA1 in the aggressive subgroup, but also down-
regulation of two RapGEFs and trends towards increased 
levels of further RapGAP molecules (Figure 6A). 
Collectively, these data suggest that Rap1 deactivation 
might represent a key characteristic of locally aggressive 
melanoma models. To further test the validity of our 
integrative approach, we chose SIPA1 which exhibited 
the strongest alteration among the Rap1-regulatory 
genes. SIPA1 protein overexpression in fast-growing 
melanoma cell models was confirmed in vitro and in 
vivo (Figure 6B,C). siRNA-mediated gene knock-down 
(Figure 6D) resulted in significantly enhanced cell 
adhesion capacity in the fast-growing SIPA1-positive 
melanoma cell model VM-1 (Figure 6E, “fast”). In 
contrast, no significant impact was detected in the slow-
growing, SIPA1-low melanoma model VM-28 (Figure 
6E, “slow”). Furthermore, clonogenic potential and cell 
migration capacity were reduced by SIPA1 blockade in the 
aggressive melanoma cell line (Figure 6F,G) while VM-28 
cells were almost incapable of migrating through the pores 
of the trans-well chambers within 48 h (Figure 6G). 
DISCUSSION
Melanoma cells constitutively harbor - besides well-
defined mutations in certain proto-oncogenes like BRAF 
and NRAS - also non-random genomic alterations reflecting 
chromosomal instability (CIN) [11, 12]. Furthermore this 
non-random aneuploidy has been suggested as a major 
driving force for melanoma development and progression 
thus representing an attractive entry point for cancer gene 
discovery [7, 9]. Using in vivo growth aggressiveness 
as a grouping criterion, we provide strong evidence that 
aneuploidy-mediated gene expression alterations are key 
drivers of aggressive melanoma growth. Our observations 
show that 1) genes exhibiting significantly altered 
expression levels in fast- versus slow-growing tumors 
are non-randomly distributed along the chromosomes; 2) 
aggressiveness-associated expression differences reflect 
copy number alterations at the corresponding DNA loci 
in the vast majority of affected genes; 3) unsupervised 
approaches based on array CGH data indeed cluster 
melanoma models according to aggressiveness; 4) the 
pattern of DNA alterations consequently allows prediction 
of in vivo growth behavior; 5) genes with different DNA 
dose and mRNA expression levels include several well-
known cancer or even melanoma genes (PTEN, NRAS, 
AURKA, ING3) [5, 11, 13, 14]. Altered gene expression 
patterns support activation of several oncogenic signaling 
pathways in the aggressive subgroup including fibroblast 
growth factor receptor (FGFR) signaling (upregulation 
of FGF1 and FGFR1, downregulation of SPRY4 and 
SPRED2), MAPK and PI3K signaling (upregulation 
of HRAS and NRAS, downregulation of PTEN), and 
deregulation of small G proteins with a focus on Rap1 
family members (upregulation of SIPA1, downregulation 
of RapGEF1 and RapGEF2), mitosis effectors (AURKA, 
INCENP) and invasion/adhesion regulation (ITGAV, 
MMP9, MMP19). 
To the best of our knowledge, this is the first study 
combining integrative genomics with in vivo growth 
aggressiveness as differentiation parameter to identify 
mechanisms and genes driving local melanoma growth 
aggressiveness. However, several other studies have used 
integrative genomic approaches to identify key factors 
driving melanoma development and/or progression. In 
agreement with our findings, these reports support the 
importance of genomic gains/losses and aneuploidy 
as driving forces in malignant transformation and 
progression [7]. Already early studies have demonstrated 
that the degree of aneuploidy and allelic loss might predict 
unfavorable prognosis [15]. Several specific chromosomal 
alterations (e.g. loss of chromosomes 6q and 10q, gains 
in chromosomes 7, 11q and 20q) were demonstrated to 
be associated with a more malignant phenotype and 
shorter patient survival [16-18]. Genome-wide array 
CGH approaches have been used to discriminate between 
nevi and melanoma [19], and specific genomic alterations 
were found to be associated with histological subtypes of 
melanoma [6], BRAF mutations [20], anatomical site as 
well as pattern of UV radiation exposure [19]. 
The melanoma models used in our study were 
derived from both primary and metastatic sites (including 
skin, lymph node, and brain) of both nodular and 
superficial spreading melanomas and almost generally 
harbored mutations in either BRAF or NRAS genes. 
Interestingly, unsupervised clustering of array CGH 
data in our melanoma set did not result in subgrouping 
according to histological subtype or stage of disease 
but rather reflected aggressiveness of in vivo growth 
behavior. This implies that gene dose is a major player in 
the deregulated expression of specific genes involved in 
melanoma progression. Corroborating observations were 
published e.g. using melanoma models from different 
species [21] or by comparing primary and metastatic 
lesions [22]. In a study by Lin et al., unsupervised 
clustering of 101 melanoma cell cultures based on 
genomic alterations led to formation of subgroups 
according to e.g. BRAF and NRAS status as well as losses 
at chromosome 10q [23]. In line with our study, multiple 
genes encoded in the GISTIC-positive regions were 
demonstrated to be deregulated at the expression level 
by SAM analysis. Besides the known BRAF mutations 
and PTEN loss also an important impact of mutations in 
FGFR1 and deregulation of negative MAPK feedback 
molecules like Spry proteins were detected [23]. Using 
a Bayesian network-based computational framework on 
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the identical data set, Akavia et al. have recently identified 
two malignancy driver genes including one Rab GTPase 
protein [24]. Of note, also in our study upregulation/gain 
of FGFR1 (together with FGF1), loss of negative MAPK 
regulators including SPRY1, SPRY2 and SPRED2, and 
deregulation of multiple small GTPases including Rab- 
and Rap-regulators were associated, in addition to PTEN 
loss, with a more aggressive melanoma phenotype. 
With regard to the intracellular signaling modules 
indicated to be deregulated in the aggressive phenotype, 
several alterations like upregulated HRAS and NRAS 
levels suggest activation of downstream signal modules 
like the PI3K and the MAPK pathways. Significantly 
decreased PTEN expression and gene dose in our fast-
growing melanomas indicate the necessity for a robust 
up-regulation of AKT downstream signals as driver 
for melanoma aggressiveness. Indeed, the PI3K/AKT/
mTOR pathway is aberrantly activated in up to 70% of 
melanomas and has been implicated in tumor progression 
and chemoresistance. Accordingly, PTEN is inactivated 
in a high proportion of melanomas through diverse 
mechanisms [25, 26].
Loss of negative MAPK regulators like Spry and 
Spred proteins suggests concerted hyperactivation of ERK 
as a driver of melanoma aggressiveness. Considering the 
wide-spread activating mutations in BRAF this observation 
was somewhat surprising especially as MAPK signal 
attenuation by Spry2 was suggested to be lost in melanoma 
cells harboring BRAFV600E [27]. Additionally, we found no 
convincingly enhanced levels of ERK phosphorylation of 
the fast- as compared to the slow-growing subgroup (data 
not shown). This argues for a regulatory role of Spry and 
Spred proteins in melanoma aggressiveness independent 
of oncogenic BRAF-driven ERK hyperactivation. Down-
regulation of Spry proteins might also enhance melanoma 
aggressiveness by supporting PI3K pathway activation. 
Thus, Edwin et al. showed that Spry2 upregulated PTEN 
expression and blocked EGF-mediated AKT activation and 
cell cycle progression [28]. Accordingly, Spry2 expression 
was decreased with colon cancer disease progression, 
and re-expression increased PTEN levels and suppressed 
growth and migration [29]. Similar to Spry, also Spred 
proteins act as inhibitors of the MAPK pathway. Spred 
overexpression has been shown to inhibit cancer motility, 
metastasis and Rho-mediated actin reorganization [30]. 
Mining of DNA and mRNA array data from our 
melanoma models suggested that changes leading to 
Rap1 deactivation might support the locally aggressive 
phenotype. For instance, expression of two Rap1 
activators (RapGEF1 and RapGEF2) was significantly 
down-regulated in the fast-growing subgroup. Among 
the deactivators, the RapGAP SIPA1 was significantly 
overexpressed and gained at the DNA level while two 
further RapGAPs (Rap1GAP1 and Rap1GAP2) were 
upregulated up to >5-fold without reaching statistical 
significance. RAP1 was originally identified as a gene able 
to reverse the malignant features of KRAS transformed 
fibroblasts [31]. However, deregulation of Rap1 via 
Rap1GEFs and Rap1GAPs might have more complex 
and even opposite impacts on tumor aggressiveness 
(reviewed in [32]). In melanoma, previously published 
data implicate both oncogenic and tumor-suppressive roles 
of Rap1 and its regulators [33-38]. Rap1 activation via 
downregulation of RapGAP1 was suggested to support 
ERK activation (even in BRAF mutant melanomas) and 
migration of melanoma cells in vitro. [35, 37]. In contrast, 
Kobayashi et al. demonstrated that Rap1 upregulation 
might induce melanoma cell death [34]. Accordingly, a 
clinicopathological study reported that high Rap1GAP 
expression might be a useful marker to identify high-
risk melanoma [33]. Additionally, ERK activation was 
demonstrated to be mediated by RAS rather than Rap1 in 
melanocytes [39]. The Rap1 regulatory gene SIPA1 (SPA-
1) was most distinctly altered at the DNA and mRNA level 
in our melanoma subgroups but has not been connected to 
melanoma before. In human solid tumors, a polymorphism 
in the SIPA1 gene causing higher RapGAP activity was 
associated with high metastatic potential of breast cancer 
[40], and SIPA1 expression was found to positively 
correlate with disease progression and metastasis in 
human prostate cancer [41]. Therefore, we decided to 
knock-down this protein in melanoma models with fast- 
and slow-growing signature. Interestingly, this led to 
enhanced cell adhesion but reduced clonogenic potential 
and migration exclusively in the fast-growing melanoma 
model, suggesting a complex role of the SIPA1/Rap1 axis 
in regulating melanoma growth and invasion. 
Taken together our study demonstrates that 
aneuploidy-driven deregulation of gene expression is one 
major driver defining the degree of local aggressiveness 
in human melanoma xenograft models. Thus non-random 
genomic alterations represent - besides activating gene 
mutations - an additional mechanism promoting concerted 
hyperactivation of major growth and survival pathways 
essential for human melanoma aggressiveness in vivo. 
MATERIALS AND METHODS
Primary cell cultures 
Primary melanoma cell cultures were established 
at the Institute of Cancer Research, Medical University 
Vienna and the Wagner Jauregg Hospital, Linz, and 
authenticated as previously described [10, 13, 42] and 
cultured in growth medium containing 10% FCS and 1% 
glutamine without antibiotics. Histological classification, 
origin, BRAFV600E and NRASQ61 mutation status of 32 
melanoma cell cultures are given in Supplementary Table 
S1. 
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Melanoma xenograft models
Subcutaneous tumor growth was initiated by 
injection of primary melanoma cells into 6-8 weeks old 
immunocompromised female mice (2.5 x 106 cells into nu/
nu mice; Iffa Credo, Charles Rivers, Arbresle, France for 
the initial 11 melanoma models; or 1 x 106 cells for all 
melanoma models into SCID/BALBc; Harlan Winkelman, 
Borchen, Germany). Each experimental group contained 
5 mice. Body weight and tumor size using a vernier 
caliper [43] were determined three times per week. All 
in vivo experiments described in the present study were 
performed on the basis of Authorization (LA1230509) of 
the Animal Ethics Committee of the Federal Department 
of Health, Nutritional Safety and Environment (Belgium) 
or according to the Austrian and FELASA guidelines for 
animal care and protection. 
Histology and immunohistochemistry
Tumor, lung, liver, kidney, and brain were removed, 
fixed in buffered formalin and embedded in paraffin 
for conventional histopathological HE staining. Three 
H&E-stained slides per organ were analyzed to look for 
metastases. Additional 5 slides through the whole piece 
were analyzed when the first screening was negative. For 
staining of tumor sections for SIPA1, the SPA-1 antibody 
(B-7, Santa Cruz) was applied using a 1:150 dilution.
Array genomic comparative hybridization (array 
CGH)
Tumor-DNA was isolated using the DNA Blood 
Mini Kit from Qiagen (Valencia, CA). Normal human 
reference DNA from multiple anonymous male donors 
was purchased from Promega (G147A, Madison, WI). 
Array CGH analyses using 4x44K oligonucleotide-based 
microarrays (Agilent, Santa Clara, CA) were performed 
according to the manufacturer`s protocol and as described 
previously [44]. Scanning was performed on a G2505B 
Micro Array Scanner (Agilent). Feature extraction and 
data analysis were carried out using the Feature Extraction 
(version 10.7.3.1) and DNA Analytics software (version 
4.0.81), respectively. Array CGH raw 2-channel (red/
green) log2-ratios were calculated and exported to Excel 
spreadsheets. Log2-ratios were used (i) as starting point for 
GISTIC analysis, (ii) as input for un-supervised clustering 
of chromosomal regions (WECCA), and (iii) for the 
supervised cluster analysis and graphical representation 
of significant loci based on un-segmented probe-level 
data. (i) GISTIC analysis [45] was performed using the 
GenePattern analysis platform at the public server of the 
Broad Institute (http://www.broadinstitute.org/cancer/
software/genepattern). Segmentation was done employing 
the CBS algorithm (GenePattern). SGOL scores (Segment 
Gain Or Loss) were calculated using a modified version of 
the GISTIC algorithm by the “SGOLscore” function in the 
“cghMCR” package for Bioconductor 2.5 using R version 
2.12.0  [46]. (ii) Unsupervised clustering segmentation 
and copy number aberrations were calculated by the 
“CGHcall” algorithm employing the “CGHraw” and 
“CGHcall” packages for Bioconductor [47]. The algorithm 
implemented in the “CGHregions” package was used for 
dimensionality reduction of the region data [47] prior to 
clustering by the WECCA (Weighted Clustering of Called 
Array CGH data) method [48]. Cluster representations and 
dendrograms were generated using the authors’ scripts for 
R (set to average linkage for agreement). (iii) Graphical 
representations of supervised clustering of un-segmented 
probe data were done with Genesis or Genespring. 
Chromosomal aberration scores were calculated using 
the Agilent software (ADM-2 algorithm) and plotted in R 
along the chromosomal positions for the comparisons with 
mean gene expression changes.
Whole genome gene expression arrays
Total RNA was isolated by Trizol/Chloroform. 
Quantity and integrity of the RNA samples was checked 
on an Agilent 2100 Bioanalyzer (RIN values were >9 
in all samples). Gene expression arrays were performed 
using 4x44K whole genome oligonucleotide-based 
gene expression microarrays (Agilent). Labeling and 
hybridization procedures were performed according to 
the instructions provided by Agilent using the Quick Amp 
Labeling Kit and the One Colour Microarray-Based Gene 
Expression Analysis Protocol. Shortly, in a first step 500 
ng of total RNA were converted into cDNA using a T7 
promoter primer. In a second labeling and amplification 
step, cDNA was converted into cRNA and labeled with 
Cy3-CTP. After purification of labeled cRNAs with the 
RNeasy Mini Kit (Qiagen), 1650 ng per sample were 
heat fragmentated for 30 min at 60°C. Hybridization 
was carried out for 17 h at 65°C in a hybridization oven. 
Afterwards, slides were washed and scanned on a G2505B 
Micro Array Scanner (Agilent). Feature extraction and 
data analysis were carried out using the Feature Extraction 
and Gene Spring software, respectively. Array raw data 
were also exported to Excel spreadsheets, normalized to 
the 75th percentile, and used for clustering in the Genesis 
1.7.5 software [49]. In cases of redundancy, data have 
been consolidated by using the probe set with the highest 
hybridization efficiency. Mean gene expression values 
(log2-ratios between the fast and slow growing groups) 
were plotted along the chromosomal positions (hg18 
coordinates from Agilent) in R.
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Real-time PCR
Real-time PCR was performed as described [43]. 
Reactions contained 20 ng cDNA and 20 µl SYBR-Green-
Power Mastermix (AppliedBiosystems, California, US) 
and 0.2 µl per primer. Reactions were set-up in triplicates 
using the following primers (100 nM): SIPA1, fw 5`-AAG 
GTG GGC ATC CTG TAC TG-3`, rev 5`-TCT CGT GGT 
CCT GGT ATG TG-3`; NUS1, fw 5`-CCA GTT AGT 
AGC CCA GAA GC-3`, rev 5`-GAT GTG CCA GGG 
AAG AAA GC-3`; DNAJC1, fw 5`-CTC AGC CAA CTG 
ACA AGA AG-3`, rev 5`-TGA GTT CGG AGA GTC TAA 
CC-3`; β-actin, fw 5`-GGA GGC AGA AGG AGA TCA 
CTG-3`, rev 5`-CGA TCC ACA CGG AGT ACT TG-3`; 
and GAPDH, fw 5`-CTG GCG TCT TCA CCA CCA T-3`, 
rev 5`-GCC TGC TTC ACC ACC TTC T-3`. PCR was 
performed on a 7500 Fast Real Time PCR System and 
results analysed in 7500 Fast System Detection Software 
(SDS) v1.4 (Applied Biosystems). For the thermal profile 
of the amplification run, following cycling conditions were 
chosen: 50°C (2 min), followed by 40 cycles with 95°C 
(15 s), 60°C (1 min). 
Western blot
Western blot was performed as described previously 
[13]. The following antibodies were used: SPA-1 (B-
7) and RAP1 (both Santa Cruz, CA); β-actin (Sigma, St 
Louis, MO). 
Suppression of SIPA1 expression by siRNA
5x105 cells were seeded into 6-well plates and 
incubated for 24 h. Cells were treated with 25 nM SIPA1 
siRNA and control scrambled siRNA according to the 
protocol provided by the manufacturer (DharmaFECT; 
Dharmacon, Lafayette, CO). After 24 h of incubation with 
siRNA, cells were counted, and the respective number of 
cells was seeded and incubated in fresh medium according 
to the respective procedures.
Cell adhesion, migration and clonogenic potential
Cell migration and clonogenic capacity of melanoma 
cells were determined as described in [43] and [50], 
respectively. For assessment of cell adhesion, cells were 
treated with siRNA as described above, and 4x103 cells 
were seeded into 96well plates for 3 h and 24 h. After this 
time, cells were washed and the medium was removed. 
After incubation of the remaining adhered cells for 24 h, 
cell viability was assessed by MTT assay as published 
[13].
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